Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service antireflux & hiatal hernia surgery cases in Pennsylvania: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 9% on average (180 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 16 | 1,113 | 47% |
| 2020 | 9 | 842 | 49% |
| 2021 | 13 | 919 | 51% |
| 2022 | 11 | 1,005 | 53% |
| 2023 | 17 | 936 | 56% |
| 2024 | 16 | 1,062 | 58% |
| 2025 from claims | – | 934 857–988 | 59% |
| 2026 forecast | – | 950 836–1,096 | 59% |
| 2027 forecast | – | 953 815–1,136 | 59% |
| 2028 forecast | – | 956 798–1,171 | 60% |
| 2029 forecast | – | 959 784–1,203 | 60% |
| 2030 forecast | – | 962 771–1,233 | 61% |
Laparoscopic fundoplication and paraesophageal hernia repair. Professional codes (what the surgeon bills): CPT 43280, 43281, 43282; the hospital bills MS-DRG 326, 327, 328.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 77% of the cases CMS names in Pennsylvania; 11 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 46% inpatient hospital, 54% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~950 | ~430 | ~520 |
| 2027 · ~950 | ~430 | ~530 |
| 2028 · ~960 | ~430 | ~530 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: hospital outpatient about 55% (54% in 2025), inpatient hospital about 45% (46% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 15 | 966−1.7%/yr | −1.7%/yr | 0.5 | 0% | 1,220 in 2030+4%/yr |
| Massachusetts | 8 | 640+1.2%/yr | +1.2%/yr | 0.7 | 0% | 1,240 in 2030+12%/yr |
| New Jersey | 7 | 492+0.3%/yr | +0.3%/yr | 0.5 | 0% | 540 in 2030+1.6%/yr |
| Connecticut | 4 | 214−7.4%/yr | −7.4%/yr | 0.6 | 0% | 200 in 2030−0.8%/yr |
| New Hampshire | 1 | 142+1.5%/yr | +1.5%/yr | 0.6 | 0% | 220 in 2030+7.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 114 | 8,075−2.5%/yr | −2.5%/yr | 6.31.1× | 4% | 8,470 in 2030+0.8%/yr |
| Cholecystectomy & appendectomy | 95 | 5,634−4%/yr | −4%/yr | 4.31.3× | 1% | 5,840 in 2030+0.6%/yr |
| Colorectal resection | 12 | 2,424−5.6%/yr | −5.6%/yr | 1.81.2× | 0% | 2,120 in 2030−2.2%/yr |
| Breast reconstruction | 1 | 565−8.2%/yr | −8.2%/yr | 0.41.0× | 0% | 800 in 2030+6.1%/yr |
| Bariatric surgery | 0 | 197−22%/yr | −22%/yr | 0.10.8× | 0% | 190 in 2030−0.9%/yr |
Antireflux & hiatal hernia surgery in every state, and its device makers · Every procedure market in Pennsylvania · Every state · Compare with New York
Johnson & Johnson MedTech leads with 81% of company spending on these surgeons in 2025, +2 pts on 2024.
In 2025, 2 companies reported engagement with Pennsylvania’s surgeons worth $2,307 in consulting, speaking, meals and travel tied to these products, about $144 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 5 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.